Dashboard
1
With ROE of 1.44%, it has a very attractive valuation with a 0.81 Price to Book Value
- Over the past year, while the stock has generated a return of -11.33%, its profits have risen by 2087.3% ; the PEG ratio of the company is 0
- At the current price, the company has a high dividend yield of 1.6
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,943 Million (Small Cap)
66.00
NA
1.28%
-0.34
1.44%
1.04
Revenue and Profits:
Net Sales:
769 Million
(Quarterly Results - Mar 2026)
Net Profit:
30 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.79%
0%
-10.79%
6 Months
-17.1%
0%
-17.1%
1 Year
-12.72%
0%
-12.72%
2 Years
-2.57%
0%
-2.57%
3 Years
-16.45%
0%
-16.45%
4 Years
-10.66%
0%
-10.66%
5 Years
-3.59%
0%
-3.59%
Jinling Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.27%
EBIT Growth (5y)
-34.23%
EBIT to Interest (avg)
39.68
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
0.81
Tax Ratio
21.65%
Dividend Payout Ratio
115.34%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.89%
ROE (avg)
3.84%
Valuation key factors
Factor
Value
P/E Ratio
66
Industry P/E
Price to Book Value
0.94
EV to EBIT
111.80
EV to EBITDA
15.23
EV to Capital Employed
0.92
EV to Sales
0.73
PEG Ratio
0.03
Dividend Yield
2.80%
ROCE (Latest)
0.82%
ROE (Latest)
1.44%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
768.70
817.20
-5.93%
Operating Profit (PBDIT) excl Other Income
20.10
8.90
125.84%
Interest
1.20
1.40
-14.29%
Exceptional Items
2.80
-10.30
127.18%
Consolidate Net Profit
29.60
-23.50
225.96%
Operating Profit Margin (Excl OI)
26.10%
-43.10%
6.92%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -5.93% vs 4.89% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 225.96% vs -196.31% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,189.20
3,275.10
-2.62%
Operating Profit (PBDIT) excl Other Income
106.30
197.80
-46.26%
Interest
7.10
3.10
129.03%
Exceptional Items
-20.90
-77.00
72.86%
Consolidate Net Profit
51.30
18.00
185.00%
Operating Profit Margin (Excl OI)
11.30%
8.70%
0.26%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -2.62% vs 2.73% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 185.00% vs -86.02% in Dec 2024
About Jinling Pharmaceutical Co., Ltd. 
Jinling Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






